C oronary artery disease (CAD) and myocardial infarction cluster within families. First-degree relatives of affected individuals are at increased risk of developing the disease themselves, with the elevated risk being of a similar magnitude regardless of whether the affected proband is a sibling or a parent. 1 Epidemiological data indicate that the estimated heritability of CAD and CAD-related death may be as high as 40% to 50%. 2 Yet, common genetic variation (≈45 loci) identified in previous genome-wide association studies (GWAS) explains only a 10th of the heritability of CAD. 3 The missing heritability may be attributable to rare genetic variants not captured by GWAS, tag single nucleotide polymorphisms (SNPs) that are not in complete linkage disequilibrium with the true causal variants, structural variation, alterations in regulatory units, epigenetic influences, gene-gene interactions, post-translational modification of proteins, or environmental and behavioral factors, including gene-environment interactions. 4 Another hypothesis is that many causally related SNPs may be discarded from GWAS-based on their failure to achieve a genome-wide statistical significance level. As pointed out by Visscher, 5 the agnostic approach epitomized by GWAS may inherently emphasize high specificity at the cost of low sensitivity (ie, it minimizes false-positive associations). A GWAS of 10 000 individuals has only 29% power to detect a SNP that explains 0.2% of the variance in a trait (at a type I error rate of 5×10 -7 ). 5 Thus, there may be a low probability (ie, 0.29 2 =0.08) that 2 independent studies of 10 000 individuals each will discover the same genetic variant. 5 The analysis of height supports the premise that GWAS may overlook some subthreshold loci (statistically speaking) that influence the trait. Height has an estimated heritability of 80%, with known SNPs (697) explaining only ≈16% of the phenotypic variation. 6 However, when all common SNP variants were considered together (≈1 million); including those below the genome-wide significance threshold the estimated heritability increases to 50%. 6 Thus, it is conceivable that common genetic variation may still explain a substantial proportion of the estimated heritability of common complex diseases, with an important contribution by variants that may not meet a stringent genome-wide significance threshold.
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In this issue, Xu et al 7 have used another approach, which they refer to as a candidate pathway-based GWAS, in their search for variants in the complement system that may be associated with CAD. By integrating a candidate gene approach and quantitative gene expression measures, the investigators demonstrate statistically significant associations of 2 regulatory SNPs related to the complement pathway components 3 and 6 (C3 and C6), respectively. In a first step, they performed a focused analysis of 668 SNPs in 32 genes related to the complement system in a case-control study of individuals of Han Chinese ancestry with and without CAD. To avoid false-negative test results, the authors used an uncorrected P<0.01 as the statistical significance threshold for proceeding to next step. Using this sequential approach, the investigators identified 2 SNPs (both P<8×10 −3 ) in the C3a anaphylatoxin chemotactic receptor 1 (C3AR1) and C6 genes that were associated with CAD status; of note, the P values for these 2 SNPs were above the threshold for statistical significance after a standard Bonferroni correction, 0.05/668=7.5−10 −5 . Next, the authors investigated if the 2 identified SNPs were associated with expression levels of the C3AR1 and C6 genes, respectively, by searching publically available databases but did not find evidence for such an association for these specific SNPs. However, the investigators identified 2 cis-expression quantitative trait loci (eQTLs) variants that were associated with C3AR1 and C6 messenger RNA (mRNA) expression levels, respectively. In a third step, the authors corroborated an association between these expression quantitative trait loci genotypes (rs7842 and rs4400166) and actual gene expression levels measured in leukocytes of 266 randomly selected individuals. In a final step, the investigators confirmed the association of rs7842 and rs4400166 with CAD in 2 additional independent case-control samples. In a meta-analysis of the latter 2 samples, the unadjusted odds ratio for prevalent CAD was 1.41, P=1.89×10 −10 for rs7842, and 1.23, P=1.69×10 −4 for rs4400166, strongly suggesting that at least genetic variation in C3AR1 is associated with CAD.
Several immune-related diseases have been associated with atherosclerotic CAD in epidemiological studies. Numerous reports also underscore the central role of systemic inflammation in the pathogenesis of CAD. 8, 9 Treatments that reduce the risk of myocardial infarction may also reduce inflammation and vice versa. 10, 11 Accordingly, the observations by Xu et al 7 are interesting and intriguing, and also biologically plausible.
Experimental evidence suggests that the complement cascade may be involved in the development of atherosclerosis, 12, 13 in part by promoting inflammation and phagocytosis of cholesterol crystals within the plaque. The activation of the complement system involves different pathways depending on the trigger (known as the classic, alternative, and lectin pathways), but all of them activate C3, which after cleavage to C3a and C3b, results in downstream activation of distal components of the cascade, including C6, C7, and C8. Of note, cholesterol crystals in the arterial wall can activate the complement system directly. 14 Circulating C3 levels have been correlated with previous myocardial infarction, stroke, and CAD, and with standard cardiovascular risk factors in unselected samples. 15, 16 C3a enhances inflammation by stimulating mast cells and the numbers of mast cells may be ≤200-fold higher at sites of plaque erosion in coronary arteries. 17 Mast cells are proatherosclerotic because they release proinflammatory cytokines within the plaques. 18 Interestingly, C6-deficient rabbits fed a cholesterol-rich diet are protected from the development of atherosclerosis. 19 These aforementioned data implicate the complement system in the pathogenesis of CAD.
The study by Xu et al 7 is an initial step toward further extending our understanding of the involvement of the complement system genes and their products in the pathogenesis of CAD using large-scale genetic data in humans. The study was based on a case-control sample of individuals of Han Chinese ancestry. In this context, it is also noteworthy that the SNPs that are associated with incident CAD may differ from those associated with prevalent CAD. Additional studies are warranted to replicate the reported findings in other ethnicities, with the evaluation of incident CAD and the incidence of other forms of cardiovascular disease, including stroke. In addition, CAD is a continuum that extends from the development of atherosclerotic plaques through the development of plaque vulnerability to the acute thrombotic events that eventually culminate in an acute myocardial infarction. The genetic determinants implicated in CAD (including the role of the complement system) may vary across this disease continuum, a premise that warrants further genetic studies investigating the underlying pathophenotypes of stable versus unstable CAD.
Perspective
The candidate pathway-based approach used by Xu et al 7 for mining extant GWAS data may help illuminate the genetic basis of CAD and bridge the gap in unexplained heritability of the condition. By focusing systematically on known biological pathways previously implicated in atherosclerosis it is conceivable that other novel genetic variants associated with CAD may be identified. This relatively inexpensive method that combines the agnostic and the candidate gene approaches can be readily applied to publically available databases. This hybrid approach may probably reveal more common variants associated with CAD than GWAS with their stringent statistical significance thresholds, but likely comes with the potential trade-off of a higher rate of false-positive findings. Replication studies are, therefore, critical when such an approach is used. Furthermore, the journey from gene/variant discovery to unraveling of variant function and then to medical inferences and clinical applications of genetic variation is a multistep process that take time. 20 Statistical associations are not necessarily causal and the downstream functional consequences of genetic variation are often unknown. Therefore, integrating multiple forms of functional genomic data beyond the exploration of expression quantitative trait loci data already done by Xu et al, 7 including but not limited to annotation of GWASdiscovered SNP data using Encyclopedia of DNA Elements (ENCODE) project data 21 (eg, targeting noncoding regulatory variation) and other -omics data (ie, metabolomics and proteomics) may help us elucidate the genetic architecture of CAD. The statistical ways of handling pathway-based analyses, including the opportunities and the pitfalls, are beyond the scope of this editorial, but are outlined elsewhere. 22 Additional studies in model systems are also warranted to investigate the functional significance of genetic variants (including those in the complement pathway). In summary, the work by Xu et al 7 highlights the importance of the many complementary approaches for identifying the complement of genes and nongenic regions implicated in the pathogenesis of CAD.
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